Nonischemic dilated cardiomyopathy (DCM) often has a genetic pathogenesis. Because of
the large number of genes and alleles attributed to DCM, comprehensive genetic testing …

Abstract Doxorubicin (DOX), or Adriamycin, an anthracycline antibiotic discovered
serendipitously as a chemotherapeutic drug several decades ago, is still one of the most …

Doxorubicin (DOX) is the most widely used anthracycline anticancer agent; however, its
cardiotoxicity limits its clinical efficacy. Numerous studies have elucidated the mechanisms …

Abstract Treatment of acute myocardial infarction (AMI) has improved significantly in recent
years, but many patients have adverse left ventricular (LV) remodeling, a maladaptive …

Current therapies for heart failure after myocardial infarction are limited and non-curative.
Although regenerative approaches are receiving significant attention, clinical efforts that …

Twenty years after the initial description of a tissue engineered construct, 3-dimensional
human cardiac tissues of different kinds are now generated routinely in many laboratories …

Despite improvements in modern cardiovascular therapy, the morbidity and mortality of
ischaemic heart disease (IHD) and heart failure (HF) remain significant in Europe and …

Mesenchymal stem cell (MSC) is an intensely studied stem cell type applied for cardiac
repair. For decades, the preclinical researches on animal model and clinical trials have …

Rationale: Virtually all mesenchymal stem cell (MSC) studies assume that therapeutic effects
accrue from local myocardial effects of engrafted MSCs. Because few intravenously …

The human heart has the least regenerative capabilities among tissues and organs, and
heart disease continues to be a leading cause of mortality in the industrialized world with …